中成药治疗气滞血瘀型稳定型心绞痛的临床综合评价  

Clinical Comprehensive Evaluation of Chinese Patent Medicines in Treatment of Stable Angina Pectoris with Qi Stagnation and Blood Stasis

作　　者：黄文娟[1] 蒋兵[1] 赵生俊[1] HUANG Wenjuan;JIANG Bing;ZHAO Shengjun(The Affiliated Hospital of Traditional Chinese Medicine,Xinjiang Medical University,Urumqi 830000,China)

机构地区：[1]新疆医科大学附属中医医院,乌鲁木齐830000

出　　处：《中国实验方剂学杂志》2024年第19期163-169,共7页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：新疆维吾尔自治区药学会科研基金计划项目(YXH202201);丝绸之路经济带创新驱动发展试验区、乌昌石国家自主创新示范区科技发展计划项目(2023LQ01002-05)。

摘　　要：目的:对10种治疗气滞血瘀型稳定型心绞痛的中成药进行临床综合评价,为优化医疗机构药品目录,促进合理用药提供参考。方法:参照《医疗机构中成药遴选专家共识2022》建立“6+1”维度的评价框架,通过三级评价细则对药品进行定性定量相结合的综合评价。结果:评价显示针对气滞血瘀型稳定型心绞痛,复方丹参滴丸、麝香保心丸、地奥心血康胶囊、血府逐瘀胶囊属于临床强推荐(分数依次为78.5、76、72、70.8分),速效救心丸、心可舒片、冠心丹参滴丸、银丹心脑通软胶囊属于临床弱推荐(分数依次为68.5、65.5、60.5、60.5分),乐脉丸、养心达瓦依米西克蜜膏评分较低暂不推荐(依次为50.5、48.8分)。整体缺乏对特殊人群、药动学参数、上市后药品再评价、经济性方面的研究。结论:随着中成药品种的更新,需要真实世界的研究数据不断增加循证支持,此次评估只能反应阶段性的综合情况,需要动态评估才能助力决策者的选择。Objective:Ten Chinese patent medicines for stable angina pectoris with qi stagnation and blood stasis were comprehensively evaluated,with the aim of providing reference for optimizing the drug list of medical institutions and promoting rational drug utilization.Method:According to the Expert Consensus on the Selection of Chinese Patent Medicines in Medical Institutions 2022,an evaluation framework of"6+1"dimensions was established for comprehensive evaluation of the drugs based on the indicators in three levels.Result:The evaluation results showed that Compound Danshen dripping pills,Shexiang Baoxin pills,Di'ao Xinxuekang capsules,and Xuefu Zhuyu capsules were strongly recommended for stable angina pectoris with Qi stagnation and blood stasis,with the scores of 78.5,76,72,and 70.8,respectively.Suxiao Jiuxin pills,Xinkeshu Tablets,Guanxin Danshen Dripping pills,and Yindan Xinnaotong soft capsules were weakly recommended,with the scores of 68.5,65.5,60.5,and 60.5 respectively.Lemai pills and Yangxin Dawayimixike migao were not recommended for the time being due to their low scores(50.5 and 48.8,respectively).There is a lack of research on special populations,pharmacokinetic parameters,post-marketing reevaluation,and economics of the medicines.Conclusion:With the updating of Chinese patent medicines,realworld research data are needed to enhance the evidence-based support.This evaluation can only reflect the comprehensive situation at a certain stage,and dynamic evaluation remains to be carried out to provide support for decision makers.

关 键 词：中成药 药品临床综合评价 冠心病心绞痛 气滞血瘀 药品遴选 

分 类 号：R284[医药卫生—中药学] R285[医药卫生—中医学] R289R287R22R2-031R33R24